Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Carboplatin and Cabazitaxel versus Lutetium-177-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CATCH-177 Trial

Trial Status: active

This phase II trial compares the effect of carboplatin and cabazitaxel to 177^ lutetium (Lu)-prostate-specific membrane antigen (PSMA)-617 in treating patients with prostate cancer that grows and continues to spread despite intervention to block hormone production (castration-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel blocks cell growth by stopping cell division and may kill tumor cells. It is a type of antimitotic agent. 177^Lu-PSMA-617, a type of radioconjugate, is a radioactive drug that binds to a protein called PSMA, which is found on some prostate cancer cells. It gives off radiation that may kill the tumor cells. The information gained from this study will help researchers learn more about 177^Lu-PSMA-617 versus carboplatin and cabazitaxel as treatment options for PSMA positive mCRPC.